Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008453:Maytansine / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D010078:Oxazines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013311:Streptozocin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010078:Oxazines; D008453:Maytansine; C007028:chlorozotocin; D013311:Streptozocin